News Sandoz launches first biosimilar Tysabri in US Biogen is facing biosimilar competition to its multiple sclerosis therapy Tysabri in the US for the first time, as Sandoz enters the market.
News Polpharma Bio gets first EU okay for Tysabri biosimilar Polpharma Biologics has said it is the first company to get approval in the EU for a biosimilar version of Biogen’s blockbuster multiple sclerosis therapy Tysabri.
Oncology ASCO 2026: Chinese firms take a front seat in oncology, with... Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
